Table 3.
First-line treatment and relative survival probability 3, 5 and 8 years after diagnosis
| Variable | Category | N (%) | 3-year | 5-year | 8-year |
|---|---|---|---|---|---|
| Survival (95% CI) | Survival (95% CI) | Survival (95% CI) | |||
| Surgery | Conservative | 1231 (73.06) | 98 (97–99) | 95 (94–97) | 93 (91–95) |
| Mastectomy | 454 (26.94) | 94 (91–97) | 89 (86–92) | 87 (82–91) | |
| Surgical margins | Negative | 1104 (65.52) | 98 (97–99) | 95 (93–97) | 94 (91–96) |
| Positive | 244 (14.48) | 100 (97–101) | 98 (94–100) | 95 (89–98) | |
| missing | 337 (20.00) | 92 (88–95) | 87 (82–90) | 82 (76–87) | |
| Chemotherapy | No | 817 (48.49) | 98 (97–100) | 96 (94–98) | 95 (91–97) |
| Neoadjuvant | 180 (10.68) | 95 (90–97) | 87 (81–92) | 83 (76–88) | |
| Adjuvant | 663 (39.35) | 99 (97–100) | 96 (94–98) | 93 (90–96) | |
| Palliative | 25 (1.48) | 40 (21–59) | 16 (5–33) | ||
| Radiotherapy | No | 334 (22.45) | 95 (92–98) | 91 (87–95) | 88 (81–93) |
| Neoadjuvant | 5 (0.34) | 61 (13–89) | 21 (1–60) | ||
| Adjuvant | 1128 (75.81) | 100 (99–100) | 97 (96–98) | 95 (93–97) | |
| Palliative | 21 (1.41) | 31 (13–52) | 16 (4–35) | ||
| Immunotherapy | No | 1498 (88.90) | 98 (97–99) | 95 (93–96) | 93 (90–95) |
| Neoadjuvant | 27 (1.60) | 90 (70–97) | 75 (54–88) | 67 (45–83) | |
| Adjuvant | 144 (8.55) | 98 (94–100) | 95 (89–98) | 92 (85–97) | |
| Palliative | 16 (0.95) | 41 (17–64) | 28 (9–51) | ||
| Endocrine therapy | No | 662 (39.29) | 94 (91–96) | 90 (87–92) | 86 (82–90) |
| Neoadjuvant | 19 (1.13) | 103 (103–103) | 76 (48–93) | 72 (40–94) | |
| Adjuvant | 985 (58.46) | 100 (99–101) | 98 (97–99) | 97 (94–99) | |
| Palliative | 19 (1.13) | 61 (35–80) | 26 (9–49) |